Update on Takayasu's arteritis

Presse Medicale

Volumn 44, Issue 6, 2015, Pages e259-e265

  Alibaz Oner, Fatma ^a   Direskeneli, Haner ^b  

^a FATIH SULTAN MEHMET TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CORTICOSTEROID; GELATINASE B; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; PENTRAXIN 3; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AORTA ARCH SYNDROME; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; GENETIC ANALYSIS; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; SCORING SYSTEM; SHORT SURVEY; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; GENETICS; SEVERITY OF ILLNESS INDEX; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; BIOMARKERS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; ISOXAZOLES; PREVALENCE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TAKAYASU ARTERITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930867517     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2015.01.015     Document Type: Short Survey

References (100)

1. Numano F. The story of Takayasu arteritis. Rheumatology (Oxford) 2002, 41:103-106.
2. Mason J.C. Takayasu arteritis-advances in diagnosis and management. Nat Rev Rheumatol 2010, 6:406-415.
3. Bicakcigil M., et al. Takayasu's arteritis in Turkey-clinical and angiographic features of 248 patients. Clin Exp Rheumatol 2009, 27:S59-S64.
4. Alibaz-Oner F., Aydin S.Z., Direskeneli H. Advances in the diagnosis, assessment and outcome of Takayasu's arteritis. Clin Rheumatol 2013, 32:541-546.
5. Ohigashi H., et al. Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients. Circ J 2012, 76:1004-1011.
6. Schmidt J., et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 2013, 88:822-830.
7. Goel R., et al. Childhood-onset Takayasu arteritis-experience from a tertiary care center in South India. J Rheumatol 2014, 41:1183-1189.
8. Grayson P.C., et al. New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol 2013, 40:1905-1912.
9. Perera A.H., et al. Optimizing the outcome of vascular intervention for Takayasu arteritis. Br J Surg 2014, 101:43-50.
10. Saadoun D., et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012, 125:813-819.
11. Sahin Z., et al. Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res Ther 2012, 14:R27.
12. Terao C., et al. Association of Takayasu arteritis with HLA-B 6701 and two amino acids in HLA-B protein. Rheumatology (Oxford) 2013, 52:1769-1774.
13. Terao C., Yoshifuji H., Mimori T. Recent advances in Takayasu arteritis. Int J Rheum Dis 2014, 17:238-247.
14. Remmers E.F., et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010, 42:698-702.
15. Hughes T., et al. Identification of multiple independent susceptibility loci in the HLA region in Behcet's disease. Nat Genet 2013, 45:319-324.
16. Saruhan-Direskeneli G., et al. Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey. Hum Immunol 2006, 67:735-740.
17. Saruhan-Direskeneli G., et al. Identification of multiple genetic susceptibility Loci in takayasu arteritis. Am J Hum Genet 2013, 93:298-305.
18. Terao C., et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 2013, 93:289-297.
19. Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990, 33:1129-1134.
20. Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 1988, 12:964-972.
21. Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?. Medicine (Baltimore) 2009, 88:221-226.
22. Kim Y.J., et al. Immunoglobulin G4-related disease with lymphoplasmacytic aortitis mimicking Takayasu arteritis. J Clin Rheumatol 2011, 17:451-452.
23. Craven A., et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 2013, 17:619-621.
24. Mustafa K.N. Takayasu's arteritis in Arabs. Clin Rheumatol 2014, 33:1777-1783.
25. Arnaud L., et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore) 2010, 89:1-17.
26. Grayson P.C., et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 2012, 71:1329-1334.
27. Arnaud L., et al. Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. Arthritis Rheum 2011, 63:1136-1140.
28. de Paula L.E., Alverne A.R., Shinjo S.K. Clinical and vascular features of Takayasu arteritis at the time of ischemic stroke. Acta Reumatol Port 2013, 38:248-251.
29. Mont'Alverne A.R., Paula L.E., Shinjo S.K. Features of the onset of Takayasu's arteritis according to gender. Arq Bras Cardiol 2013, 101:359-363.
30. Clemente G., et al. Takayasu arteritis in a Brazilian multicenter study: children with a longer diagnosis delay than adolescents. Clin Exp Rheumatol 2014, 32:S128-S133.
31. Lee G.Y., et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol 2012, 159:14-20.
32. Sun T., et al. Coronary artery involvement in takayasu arteritis in 45 Chinese patients. J Rheumatol 2013, 40:493-497.
33. Park J.K., et al. Incidence of malignancy in Takayasu arteritis in Korea. Rheumatol Int 2014, 34:517-521.
34. Mandal D., et al. Takayasu arteritis in pregnancy: an analysis from eastern India. Arch Gynecol Obstet 2012, 285:567-571.
35. Hidaka N., et al. Clinical manifestations of pregnancy in patients with Takayasu arteritis: experience from a single tertiary center. Arch Gynecol Obstet 2012, 285:377-385.
36. Alpay-Kanitez N., et al. Favourable pregnancy outcome in Takayasu arteritis: a single centre experience. Clin Exp Rheumatol 2014, [Epub ahead of print, PMID: 25236472].
37. Maksimowicz-McKinnon K. New insights into the pathogenesis and treatment of Takayasu arteritis. Expert Rev Clin Immunol 2009, 5:445-449.
38. Kim Y.W., et al. Surgical bypass vs. endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 2012, 55:693-700.
39. Kerr G.S., et al. Takayasu arteritis. Ann Intern Med 1994, 120:919-929.
40. Direskeneli H., et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011, 38:1471-1479.
41. Luqmani R.A., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-678.
42. Quartuccio L., et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012, 30:922-928.
43. Merkel P.A., et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011, 38:1480-1486.
44. Misra R., et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013, 52:1795-1801.
45. Aydin S.Z., et al. Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology (Oxford) 2010, 49:1889-1893.
46. Direskeneli H., Aydin S.Z., Merkel P.A. Disease assessment in Takayasu's arteritis. Rheumatology (Oxford) 2013, 52:1735-1736.
47. Grayson P.C., et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol 2012, 39:303-309.
48. Schmidt W.A. Imaging in vasculitis. Best Pract Res Clin Rheumatol 2013, 27:107-118.
49. Mavrogeni S., et al. The role of multimodality imaging in the evaluation of Takayasu arteritis. Semin Arthritis Rheum 2013, 42:401-412.
50. Hartlage G.R., et al. Multimodality imaging of aortitis. JACC Cardiovasc Imaging 2014, 7:605-619.
51. Papa M., et al. Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. AJR Am J Roentgenol 2012, 198:W279-W284.
52. Tso E., et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002, 46:1634-1642.
53. Eshet Y., et al. The limited role of MRI in long-term follow-up of patients with Takayasu's arteritis. Autoimmun Rev 2011, 11:132-136.
54. Santhosh S., et al. F-18 FDG PET/CT in the evaluation of Takayasu arteritis: an experience from the tropics. J Nucl Cardiol 2014, 21:993-1000.
55. Karapolat I., et al. Comparison of F18-FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis. Clin Exp Rheumatol 2013, 31:S15-S21.
56. Tezuka D., et al. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 2012, 5:422-429.
57. Lee K.H., et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis. Arthritis Rheum 2012, 64:866-875.
58. Cheng Y., et al. 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol 2013, 31:S22-S27.
59. Fuchs M., et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012, 39:344-353.
60. Arnaud L., et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis?. Arthritis Rheum 2009, 60:1193-1200.
61. Bacon P., Direskeneli H. Quantifying disease involvement in Takayasu's arteritis. Rheumatology (Oxford) 2014, 53:1535-1536.
62. Seyahi E., et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006, 65:1202-1207.
63. Seyahi E., et al. Aortic and coronary calcifications in Takayasu arteritis. Semin Arthritis Rheum 2013, 43:96-104.
64. Schinkel A.F., et al. Utility of contrast-enhanced ultrasound for the assessment of the carotid artery wall in patients with Takayasu or giant cell arteritis. Eur Heart J Cardiovasc Imaging 2014, 15:541-546.
65. Alibaz-Oner F., et al. Impaired endothelial function in patients with Takayasu's arteritis. Acta Cardiol 2014, 69:45-49.
66. Sinha D., et al. Development of a colour Doppler ultrasound scoring system in patients of Takayasu's arteritis and its correlation with clinical activity score (ITAS 2010). Rheumatology (Oxford) 2013, 52:2196-2202.
67. Comarmond C., et al. Myocardial perfusion imaging in takayasu arteritis. J Rheumatol 2013, 40:2052-2060.
68. Comarmond C., et al. Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis. Am J Cardiol 2014, 113:881-887.
69. Mekinian A., et al. Pulmonary perfusion scintigraphy: a tool to detect the presence of pulmonary artery involvement in Takayasu's arteritis. Presse Med 2012, 41:e37-e42.
70. Kang E.J., et al. Takayasu arteritis: assessment of coronary arterial abnormalities with 128-section dual-source CT angiography of the coronary arteries and aorta. Radiology 2014, 270:74-81.
71. Addimanda O., et al. Pulmonary artery involvement in Takayasu arteritis, PET/CT versus CT angiography. Clin Exp Rheumatol 2013, 31:S3-S4.
72. Schneeweis C., et al. Delayed contrast-enhanced MRI of the coronary artery wall in takayasu arteritis. PLoS One 2012, 7:e50655.
73. Dogan S., et al. Markers of endothelial damage and repair in Takayasu arteritis: are they associated with disease activity?. Rheumatol Int 2014, 34(8):1129-1138. 10.1007/s00296-013-2937-3.
74. Yilmaz H., et al. Ghrelin and adipokines as circulating markers of disease activity in patients with Takayasu arteritis. Arthritis Res Ther 2012, 14:R272.
75. Ishihara T., et al. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 2013, 77:477-483.
76. Sun Y., et al. MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. Int J Cardiol 2012, 156:236-238.
77. da Silva T.F., et al. High prevalence of metabolic syndrome in Takayasu arteritis: increased cardiovascular risk and lower adiponectin serum levels. J Rheumatol 2013, 40:1897-1904.
78. Tripathy N.K., Sinha N., Nityanand S. Interleukin-8 in Takayasu's arteritis: plasma levels and relationship with disease activity. Clin Exp Rheumatol 2004, 22:S27-S30.
79. Ishihara T., et al. Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 2011, 57:1712-1713.
80. Dagna L., et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011, 155:425-433.
81. Youngstein T., et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-alpha and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 2014, 32:S11-S18.
82. Direskeneli H., Aydin S.Z., Merkel P.A. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol 2011, 29:S86-S91.
83. Yilmaz N., et al. Impaired quality of life, disability and mental health in Takayasu's arteritis. Rheumatology (Oxford) 2013, 52:1898-1904.
84. Akar S., et al. Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. Clin Rheumatol 2008, 27:859-865.
85. Abularrage C.J., et al. Quality of life of patients with Takayasu's arteritis. J Vasc Surg 2008, 47:131-136. [discussion 136-7].
86. Alibaz-Oner F., et al. Presence of fibromyalgia in patients with Takayasu's arteritis. Intern Med 2013, 52:2739-2742.
87. Keser G., Direskeneli H., Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford) 2014, 53:793-801.
88. Mukhtyar C., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:318-323.
89. Clifford A., Hoffman G.S. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014, 26:7-15.
90. de Souza A.W., et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012, 41:227-230.
91. Salvarani C., et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012, 30:S90-S93.
92. Unizony S., et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012, 64:1720-1729.
93. Tombetti E., et al. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013, 40:2047-2051.
94. Canas C.A., et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 2014, 20:125-129.
95. Goel R., et al. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis 2013, 16:754-761.
96. Abisror N., et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013, 12:1143-1149.
97. Youngstein T., Mason J.C. Interleukin 6 targeting in refractory Takayasu arteritis: serial noninvasive imaging is mandatory to monitor efficacy. J Rheumatol 2013, 40:1941-1944.
98. Renauer P.A., Saruhan-Direskeneli G., Coit P., Adler A., Aksu K., Keser G., et al. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a Genome-Wide Association Study. Arthritis Rheumatol 2015, 67(5):1361-1368. [PMID: 25604533; PMCID: PMC4414813]. 10.1002/art.39035.
99. Terao C., Matsumura T., Yoshifuji H., Kirino Y., Maejima Y., Nakaoka Y., et al. Takayasu arteritis and ulcerative colitis-high concurrence ratio and genetic overlap. Arthritis Rheumatol 2015, [PMID: 25931203 (Epub ahead of print)]. 10.1002/art.39157.
100. Saadoun D., Garrido M., Comarmond C., Desbois A.C., Domont F., Savey L., et al. Th1 and th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 2015, 67(5):1353-1360. [PMID: 25604824]. 10.1002/art.39037.